Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly Wang

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Ebiomedicine|August 25, 2023
Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIVAdrienne E Swanstrom, Robert J Gorelick, Jorden L Welker, et al.
Nature|December 7, 2021
Long-acting capsid inhibitor protects macaques from repeat SHIV challengesSamuel J Vidal, Elena Bekerman, Derek Hansen, et al.
Hepatology Communications|February 19, 2025
Liver involvement in a large cohort of patients with erythropoietic protoporphyria or X-linked protoporphyriaCynthia Levy, Hetanshi Naik, Jessica Overbey, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2019
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi<sup>®</sup>James G Taylor, Sheila Zipfel, Kyla Ramey, et al.
Journal of Primary Care & Community Health|September 13, 2024
Feasibility and Methodology of a Pilot Free Blood Pressure Monitoring and Follow-Up Program at Two Free ClinicsGeorgios Mikos, Brian Yu, Jessica Balbin, et al.
Journal of Medicinal Chemistry|October 1, 2025
Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, Winston Tse, Scott D Schroeder, et al.
Plos One|June 25, 2025
Multi-region investigation of 'man' as default in attitudesCurtis Edward Phills, Jeremy K Miller, Erin M Buchanan, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Medicinal Chemistry|December 11, 2013
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infectionJohn O Link, James G Taylor, Lianhong Xu, et al.
Ebiomedicine|August 25, 2023
Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIVAdrienne E Swanstrom, Robert J Gorelick, Jorden L Welker, et al.
Nature|December 7, 2021
Long-acting capsid inhibitor protects macaques from repeat SHIV challengesSamuel J Vidal, Elena Bekerman, Derek Hansen, et al.
Hepatology Communications|February 19, 2025
Liver involvement in a large cohort of patients with erythropoietic protoporphyria or X-linked protoporphyriaCynthia Levy, Hetanshi Naik, Jessica Overbey, et al.
Bioorganic & Medicinal Chemistry Letters|May 29, 2019
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi<sup>®</sup>James G Taylor, Sheila Zipfel, Kyla Ramey, et al.
Journal of Primary Care & Community Health|September 13, 2024
Feasibility and Methodology of a Pilot Free Blood Pressure Monitoring and Follow-Up Program at Two Free ClinicsGeorgios Mikos, Brian Yu, Jessica Balbin, et al.
Journal of Medicinal Chemistry|October 1, 2025
Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, Winston Tse, Scott D Schroeder, et al.
Plos One|June 25, 2025
Multi-region investigation of 'man' as default in attitudesCurtis Edward Phills, Jeremy K Miller, Erin M Buchanan, et al.
Pageof 5